Form 4: Castle Biosciences Director Daniel Bradbury Sells Shares Under 10b5-1 Plan

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on October 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Daniel Bradbury, a director at Castle Biosciences, sold shares of the company's common stock on October 7, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 10, 2024.
• A total of 5,017 shares were sold directly at a weighted-average price of $29.443, with individual transaction prices ranging from $29.18 to $29.79.
• An additional 1,425 shares held by Daniel Bradbury Irrecovable Descendant's Trust and 1,425 shares held by Annette Bradbury Irrecovable Descendant's Trust were sold.
• Following the reported transactions, Bradbury directly owns no shares, indirectly owns 20,068 shares through BioBrit, LLC, 5,700 shares through Daniel Bradbury Irrecovable Descendant's Trust, 5,700 shares through Annette Bradbury Irrecovable Descendant's Trust and 13,291 shares through The Bradbury Family Trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to insider trading. It doesn't inherently convey positive or negative sentiment, as it simply reports transactions.

Industry Context

This filing is a routine disclosure of insider trading activity. It is common for corporate insiders to use 10b5-1 plans to sell shares over time to avoid accusations of trading on non-public information.

Stakeholder Impact

• The share sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates